Enfortumab Vedotin
• Antibody-drug conjugate
• Target is Nectin-4, highly expressed in urothelial carcinoma
• Monoclonal antibody and monomethyl auristatin E (MMAE)
• Microtubule disrupting agent
• Clinical benefit previously demonstrated in phase I / II
studies
• Durable clinical responses noted